U.S. markets close in 1 hour 11 minutes

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.33+0.18 (+1.77%)
As of 2:48PM EDT. Market open.
Sign in to post a message.
  • j
    jesus
    Jefferies analyst Andrew Tsai said the news of Athira Pharma CEO Leen Kawas being placed on temporary leave amid a review by the board on her doctoral research is an "unusual situation," but Tsai prefers to wait for more details before re-evaluating his positive thesis around '1017 for Alzheimer's. After having spokes to COO Mark Litton, Tsai noted that the company points out that all preclinical and clinical work around '1017 is completely separate from the doctoral research, including the "compelling" Phase I P300 data. Tsai has a Buy rating and $40 price target on Athira Pharma
    Bullish
  • n
    n
    Inside knowledge is Atha has new data. Once released to the public and the CEO has been dismissed this will be back to over $20
    Bullish
  • M
    Mick 69
    Anybody here? LOL I have the feeling most retail investors have sold. This company has great potential.
    Bullish
  • S
    StephenUK
    Very positive results just published by ATHA in their poster presentation at AAIC and available on their website.
    “As measured by qEEG, ATH-1017 induced a fast onset and sustained gamma power induction across a range of active doses in humans and animals based on equivalent PK exposures.”
  • d
    d
    ATHA presenting at international Alzheimer’s conference today. Shared this poster with early trial results. Looks promising!

    https://investors.athira.com/static-files/45c3f385-0012-422e-90f3-b7855c84ec8a
    Bullish
  • m
    mooch
    Providing updates is clearly not a priority for them at this point
  • J
    JohnP
    WSU is the reason there has been such a drop. They evidently are trying to obtain ATHA at a lower price to make a statement in a PR. They have known about this discrepancy for years and have done nothing so they cannot do it now. There is either a buyout on the horizon or some large investors getting more. The scared shares are gone, institutions have increased their percentage and the column has dried up on a company that is about to make some tremendous headway in the pharma market. Shame on the for stealing small investors money.
  • J
    Joe
    Can anyone on this board discuss the dozens of lawsuits against the company now, with an assessment and opinion of how those many pending lawsuits can likely impact the company over next 12 months?
  • S
    StephenUK
    ATHA is bubbling along nicely now in anticipation of AAIC conference next week. It could be a very good week. Any positive update and this should fly. Good luck all and always do your due diligence.
    Bullish
  • L
    Learner
    Please stay in double digits...still red for me till 13 but still feels better...lol
  • L
    Learner
    Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
  • S
    StephenUK
    ATH-1017 Clinical Results

    Athira’s completed Phase 1a/b clinical trials of ATH-1017 for the treatment of Alzheimer’s disease established that the treatment was generally well tolerated at all tested doses. Measures evaluating brain activity by electroencephalogram (qEEG) also produced a strong suite of translational data. Additionally, a statistically significant improvement in Event-Related Potential (ERP) P300 latency, a functional measure of working memory processing speed and executive function, was noted in patients with Alzheimer’s disease following multiple dose treatments with ATH-1017 compared with those receiving placebo. Athira is seeking to confirm a connection between P300 latency improvement and clinical cognitive benefit by ATH-1017 treatment.
    Bullish
  • M
    Mick 69
    Below is the reason why I bought ATHA;

    We have a lot to discuss and not a lot of mind space to address it with. I led with the idea of why I went after ATHA in the alert for HROW. The idea is two fold, first and most importantly the Alzheimer’s stocks are really ripping. SAVA is a holding in stocks Under $10 as most of you know, and it looks poised to return to all time highs in the triple digits.
    The next idea is that ATHA has developed a therapy for Alzheimer’s and it has passed a phase 1 trial and entering into phase 2. Regardless of what the CEO wrote in her doctoral thesis, this fact will remain to be true.
    A lot of people on social media will say that you can no longer trust management at all for this company and that the stench of fraud is in the air. I see it another way, the board moved quickly and investigated the claims and appointed the COO as the temporary head of the company.
    I don’t believe that ATHA is a fraud… more like it was an opportunity that I didn’t want to pass up on. The stock has been slammed and if they get some good results we could easily see this stock double in value.
  • M
    Mick 69
    Why is this selling before the conference?
  • M
    Mick 69
    Can we contact the company for explanation
  • l
    l
    ATHA will be like CCXI, just give it some time to recover.
  • M
    Mick 69
    one day red the other is green and VS LOL
    Bullish
  • L
    Learner
    I hope it goes back to 18 soon...
  • A
    Amir
    So I see some buying sign which could be inside buying